The estimated Net Worth of Christian S Schade is at least $4.62 Million dollars as of 18 May 2022. Mr. Schade owns over 37,500 units of Aprea Therapeutics stock worth over $942,224 and over the last 19 years he sold APRE stock worth over $0. In addition, he makes $3,677,570 as Chairman of the Board, President, and Chief Executive Officer at Aprea Therapeutics.
Christian has made over 6 trades of the Aprea Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 37,500 units of APRE stock worth $24,000 on 18 May 2022.
The largest trade he's ever made was buying 37,500 units of Aprea Therapeutics stock on 18 May 2022 worth over $24,000. On average, Christian trades about 2,718 units every 86 days since 2006. As of 18 May 2022 he still owns at least 292,616 units of Aprea Therapeutics stock.
You can see the complete history of Mr. Schade stock trades at the bottom of the page.
Christian S. Schade serves as Chairman of the Board, President, Chief Executive Officer of the Company. Mr. Schade has more than 30 years of private and public pharmaceutical and biotechnology industry experience, as well as broad corporate finance expertise from his tenure in investment banking. Prior to joining Aprea, from 2014 to 2015, he was Chief Executive Officer of Novira, a privately held antiviral drug discovery company until it was acquired by Johnson & Johnson. Prior to joining Novira, Mr. Schade was Executive Vice President and Chief Financial Officer of Omthera Pharmaceuticals, Inc. (“Omthera”), a NASDAQ-listed specialty pharmaceuticals company focused on the development and commercialization of new therapies for dyslipidemia. At Omthera, Mr. Schade was responsible for all corporate finance, accounting and business development activities, and led the sale of Omthera in July 2013 to AstraZeneca Plc. He also was Executive Vice President and Chief Financial Officer at NYSE-listed NRG Energy Inc., and from 2000 to 2009, he was Senior Vice President of Administration and Chief Financial Officer at Medarex, Inc. (“Medarex”), a biopharmaceutical company focused on antibody-based therapeutic products for oncology, inflammation, autoimmune disorders and infectious diseases. Mr. Schade played a pivotal role in the acquisition of Medarex by Bristol-Myers Squibb Company, leading the negotiations for the sale and the eventual merger-integration process of the research, development and administrative functions. Before joining Medarex, Mr. Schade served as Managing Director at Merrill Lynch in London and held various corporate finance and capital markets positions in New York and London for both Merrill Lynch and JP Morgan Chase & Co. Mr. Schade currently serves on the board of directors of Sapience Therapeutics, Inc. and Integra LifeSciences Inc. (Nasdaq: IART) where he chairs the Finance Committee. Mr. Schade received an M.B.A. from the Wharton School at the University of Pennsylvania and an A.B. from Princet
As the Chairman of the Board, President, and Chief Executive Officer of Aprea Therapeutics, the total compensation of Christian Schade at Aprea Therapeutics is $3,677,570. There are no executives at Aprea Therapeutics getting paid more.
Christian Schade is 59, he's been the Chairman of the Board, President, and Chief Executive Officer of Aprea Therapeutics since 2020. There are 8 older and 9 younger executives at Aprea Therapeutics. The oldest executive at Aprea Therapeutics, Inc. is Guido Magni, 67, who is the Independent Director.
Christian's mailing address filed with the SEC is 1100 CAMPUS ROAD, , PRINCETON, NJ, 08540.
Over the last 5 years, insiders at Aprea Therapeutics have traded over $63,126,246 worth of Aprea Therapeutics stock and bought 2,073,560 units worth $29,606,912 . The most active insiders traders include Group, Llc Green Jeremy Red..., Vantage I, L.P.Versant Vant..., and John B Iii Henneman. On average, Aprea Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $420,918. The most recent stock trade was executed by John P. Hamill on 13 March 2024, trading 1,010 units of APRE stock currently worth $7,363.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Aprea Therapeutics executives and other stock owners filed with the SEC include: